GlassScriptPhysician profile
Ritu M Chitakki
NPI 1609823798
$6,462.65
in general payments reported to CMS, 2019-2025
22 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $744 · 2021: $970 · 2022: $1,132 · 2023: $1,101 · 2024: $979 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,546.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,385.98 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $996.42 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.20 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $316.00 | 2022-2023 | |
| Pfizer INC. | $277.16 | 2019-2025 | |
| Amgen INC. | $253.51 | 2019-2021 | |
| Daiichi Sankyo INC. | $236.79 | 2021-2023 | Injectafer |
| Exact Sciences Corporation | $222.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $207.42 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $135.93 | 2022-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $126.26 | 2019-2022 | |
| Abbvie INC. | $62.63 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.93 | 2022 | |
| Amarin Pharma, INC. | $54.76 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.28 | 2019 | |
| Abbott Laboratories | $24.03 | 2023 | Freestyle Libre 2 |
| Bausch Health US, LLC | $20.91 | 2021 | |
| Horizon Therapeutics Plc | $16.76 | 2021 | |
| Glaxosmithkline, LLC. | $16.29 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $12.57 | 2019 | |
| Phadia US INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Chitakki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.